About BioMarin Pharmaceutical Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biomarin.com/
Frequently Asked Questions
What is the 52-week range for BMRN?
The 52-week high is $70.98 and the 52-week low is $49.26.
What is the P/E ratio for BMRN?
The Price to Earnings (P/E) ratio is 152.93.
What is the dividend yield for BMRN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 1.18%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 2.14%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.88.
Analyst Recommendation Trends
Wall Street analyst consensus for BMRN over the last few months:
Latest BMRN News
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.
BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented
The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs despite volatility from a Federal Reserve leadership transition and Middle East tensions. Markets rebounded from Q1 lows, […]
BioMarin and Profluent partner on AI-designed enzyme therapies
Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates.
BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed
https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm
Profluent Partners With BioMarin to Design Novel Medicines Using AI
EMERYVILLE, Calif., September 30, 2026--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational AI models to generate novel potential drug candidates, and BioMarin will screen the results with the goal to eventually advance the most promising designs.
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.
3 Healthcare Stocks That Fall Short
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.9% gain over the past six months, beating the S&P 500 by 25.5 percentage points.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
Tracking John Paulson's Paulson & Company Portfolio: Q2 2026 Update
John Paulsonâs Q2 2026 13F portfolio fell to ~$2.58B, with 8 holdings and a concentrated top five making up ~92%. Click to read this analysis on the portfolio.
Travere Therapeutics Announces Planned Chief Executive Officer Transition
SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy for BioMarin Pharmaceutical, with the share price down 7.77% over 30 days, even after a 16.91% 90 day share price return and a 17.62% total shareholder return over the past year. This points to momentum cooling in the short term despite...
Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?
BioMarin Pharmaceutical recently reported positive Phase 3 CANOPY-HCH-3 results for VOXZOGO in children with hypochondroplasia and submitted a supplemental FDA application to expand the drug’s use, while also adding Bristol Myers Squibb research leader Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee. The combination of strong late-stage VOXZOGO data in an indication with no approved treatments and the addition of a seasoned R&D executive to the board underscores...
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth plans for newly acquired rare-disease products, VOXZOGO and several pipeline programs at Morgan Stanley
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
BioMarin Stops Voxzogo Development for Noonan Syndrome
BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
Ascendis Pharma: Back To Full Independence
Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and disappointments. Read more on ASND stock here.
BioMarin Pharmaceutical Decides To Discontinue Development Of VOXZOGO For Children With Noonan Syndrome
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after assessing a number of
3 Mid-Cap Stocks We Keep Off Our Radar
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, effective September 10, 2026.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsAlexander...
BioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicals
ChartMill: BioMarin stock scores 8/10 technicals and 9/10 setup, showing a tight base with clear entry and stop levels for a potential breakout watch.
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]
Growth Without AI: 8 Stock Picks
With products ranging from cardboard boxes to new drugs, these companies are all on track to double their earnings.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 1:00 PM EDTCompany ParticipantsCristin Hubbard -...
BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:20 AM EDTCompany ParticipantsCristin...
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 3:00 PM EDTCompany ParticipantsGregory Friberg -...
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting. The data included new results on the magnitude of benefit seen in children receiving VOXZOGO, including statistically significant improvements in annualized growth ve
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC
Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead
BioMarin Pharmaceutical trades at $66.53 and has moved in lockstep with the market. Its shares have returned 9.3% over the last six months while the S&P 500 has gained 13.6%.
3 Value Stocks We Think Twice About
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]
EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock
Eric George Davis, EVP at BioMarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on September 3, according to a new SEC filing. What Happened: Davis opted to sell 17,557 shares of BioMarin Pharmaceutical,
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing
Ascendis Pharma (NasdaqGS:ASND) reached a global settlement and licensing agreement with BioMarin Pharmaceutical that resolves worldwide patent disputes related to Yuviwel. The deal grants Ascendis Pharma a license to continue commercializing Yuviwel and related products across global markets. Ascendis Pharma also received a positive reimbursement recommendation in Canada for Yorvipath for adults with chronic hypoparathyroidism. These legal and reimbursement outcomes affect Ascendis Pharma's...
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors
SAN DIEGO, September 03, 2026--Avenzo Therapeutics Announces Appointment of Barbara Bodem and Elizabeth Mily to Board of Directors as Independent Directors
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target
Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Friberg Gregory R | -4,086 | $60 | $245,160 |
| 2026-09-10 | Plenge Robert M | +6,140 | - | - |
| 2026-09-02 | Davis George Eric | -17,557 | $66.284 | $1,163,748 |
| 2026-06-02 | Countouriotis Athena | +7,490 | - | - |
| 2026-06-02 | Walbert Timothy P | +7,490 | - | - |
| 2026-06-02 | Ho Maykin | +7,490 | - | - |
| 2026-06-02 | HOMBACH ROBERT J. | +7,490 | - | - |
| 2026-06-02 | Enyedy Mark J | +7,490 | - | - |
| 2026-06-02 | Dere Willard H | +7,490 | - | - |
| 2026-06-02 | CLARK IAN T | +7,490 | - | - |
| 2026-06-02 | Bodem Barbara W. | +7,490 | - | - |
| 2026-06-02 | ANDERSON ELIZABETH M | +7,490 | - | - |
| 2026-05-20 | Hubbard Cristin | -2,318 | $50.2 | $116,364 |
| 2026-05-07 | Friberg Gregory R | -3,281 | $53.85 | $176,682 |
| 2026-03-18 | Davis George Eric | -1,273 | $56.05 | $71,352 |
| 2026-03-17 | Guyer Charles Greg | -1,693 | $56.05 | $94,893 |
| 2026-03-17 | Mueller Brian | -2,117 | $56.05 | $118,658 |
| 2026-03-17 | Hardy Alexander | -4,252 | $56.05 | $238,325 |
| 2026-03-17 | Hubbard Cristin | -1,245 | $56.05 | $69,782 |
| 2026-03-17 | Friberg Gregory R | -1,629 | $56.05 | $91,305 |
| 2026-03-16 | Hubbard Cristin | +36,680 | - | - |
| 2026-03-16 | Hubbard Cristin | +15,410 | - | - |
| 2026-03-16 | Friberg Gregory R | +45,600 | - | - |
| 2026-03-16 | Friberg Gregory R | +19,150 | - | - |
| 2026-03-16 | Guyer Charles Greg | +35,680 | - | - |
| 2026-03-16 | Guyer Charles Greg | +14,990 | - | - |
| 2026-03-16 | Davis George Eric | +34,690 | - | - |
| 2026-03-16 | Davis George Eric | +14,570 | - | - |
| 2026-03-16 | Davis George Eric | -7,177 | $58.51 | $419,926 |
| 2026-03-16 | Mueller Brian | +44,600 | - | - |
| 2026-03-16 | Mueller Brian | +18,740 | - | - |
| 2026-03-16 | Hardy Alexander | +89,200 | - | - |
| 2026-03-16 | Hardy Alexander | +62,440 | - | - |
| 2026-03-13 | Guyer Charles Greg | -9,109 | $58.51 | $532,968 |
| 2026-03-13 | Mueller Brian | -9,945 | $58.51 | $581,882 |
| 2026-03-13 | Hardy Alexander | -2,941 | $58.51 | $172,078 |
| 2026-03-11 | Guyer Charles Greg | -16,486 | $60.46 | $996,744 |
| 2026-02-26 | Friberg Gregory R | -6,326 | $60.3758 | $381,937 |
| 2026-02-26 | Davis George Eric | -26,061 | $61.36 | $1,599,103 |
| 2026-02-25 | Guyer Charles Greg | +2,371 | - | - |
| 2026-02-25 | Guyer Charles Greg | +6,675 | - | - |
| 2026-02-25 | Guyer Charles Greg | +6,176 | - | - |
| 2026-02-25 | Davis George Eric | +2,372 | - | - |
| 2026-02-25 | Davis George Eric | +6,675 | - | - |
| 2026-02-25 | Davis George Eric | +6,177 | - | - |
| 2026-02-25 | Mueller Brian | +2,569 | - | - |
| 2026-02-25 | Mueller Brian | +7,230 | - | - |
| 2026-02-25 | Mueller Brian | +6,683 | - | - |
| 2026-01-20 | Ramchandani Rashmi Virendra | +18,220 | - | - |
| 2026-01-20 | Ramchandani Rashmi Virendra | +7,070 | - | - |
| 2026-01-20 | Ramchandani Rashmi Virendra | +18,540 | - | - |
| 2025-12-30 | MEIER RICHARD A | -500 | - | - |
| 2025-12-01 | Hardy Alexander | -16,570 | $55.03 | $911,847 |
| 2025-10-31 | Hubbard Cristin | +80 | $45.535 | $3,643 |
| 2025-10-31 | Guyer Charles Greg | +62 | $45.535 | $2,823 |
| 2025-10-31 | Friberg Gregory R | +398 | $45.535 | $18,123 |